||| schreef op 30 december 2016 09:28:
"Treatment of Hereditary Angioedema with C1 Inhibitor" in Patent Application Approval Process (USPTO 20160361394)
12/29/2016 | 11:51 pm
By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A patent application by the inventor Totoritis, Mark C. (Rancho Santa Fe, CA), filed on February 27, 2015, was made available online on December 22, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents (see also Biotechnology Companies).
This patent application is assigned to Santarus, Inc.
The following quote was obtained by the news editors from the background information supplied by the inventors: "Human C1 inhibitor (C1INH), also known as C1 esterase inhibitor, is a substance in the superfamily of serine proteinase inhibitors. The production of recombinant C1 inhibitor in the milk of a transgenic nonhuman mammal (rhC1INH) is disclosed in U.S. Pat. No. 7,067,713. That patent also indicates that the C1 inhibitor (or its recombinant preparation) is useful in treating patients with HAE or patients requiring immunosuppression.'
Santarus??... ( mag hopen dat dit een vaudje is...?)
appft.uspto.gov/netacgi/nph-Parser?Se...